COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological